AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34917633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 35285397 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hydrotherapy combined with aquatic lower extremity strength training
Number of subjects: 56
Study 35285397 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydrotherapy
Number of subjects: 56
Study 33468518 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention for self-monitoring of blood pressure (305 participants)
Number of subjects: 622
Study 33468518 — intervention group
Group type: COMPARATOR
Intervention: Usual care (317 participants)
Number of subjects: 622
Study 36369323 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body Photobiomodulation (PBM)
Number of subjects: 42
Study 36369323 — intervention group
Group type: COMPARATOR
Intervention: Placebo PBM
Number of subjects: 42
Study 33588594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 or 110 mg BID)
Number of subjects: 988
Study 33588594 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg QD)
Number of subjects: 988
Study 36323305 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator
Number of subjects: 20
Study 33017580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose quadruple combination therapy (quadpill) containing irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg
Number of subjects: 650
Study 33017580 — intervention group
Group type: COMPARATOR
Intervention: Control therapy of a single identical-appearing pill containing irbesartan 150 mg
Number of subjects: 650
Study 33017580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms will provide step-up therapy of open-label amlodipine 5 mg if blood pressure is >140/90 at 6 weeks
Number of subjects: 650
Study 35120864 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM intervention (6 visits with pharmacist-technician team)
Number of subjects: 576
Study 35120864 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM intervention
Number of subjects: 576
Study 35120864 — intervention group
Group type: COMPARATOR
Intervention: Control (printed information only)
Number of subjects: 576
Study 35142630 — intervention group
Group type: EXPERIMENTAL
Intervention: app+classes
Number of subjects: 211
Study 35142630 — intervention group
Group type: EXPERIMENTAL
Intervention: app‐only
Number of subjects: 211
Study 35142630 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 211
Study 33638647 — intervention group
Group type: EXPERIMENTAL
Intervention: non-faith-based abstinence-only
Number of subjects: 613
Study 33638647 — intervention group
Group type: EXPERIMENTAL
Intervention: faith-based abstinence-only
Number of subjects: 613
Study 33638647 — intervention group
Group type: COMPARATOR
Intervention: attention-matched health-promotion control
Number of subjects: 613
Study 32374030 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC-2 (10 mg macitentan/40 mg tadalafil)
Number of subjects: 0
Study 32374030 — intervention group
Group type: COMPARATOR
Intervention: Single-component tablets of macitentan (10 mg) and tadalafil (40 mg)
Number of subjects: 0
Study 35093678 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (N=797)
Number of subjects: 1554
Study 35093678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=484)
Number of subjects: 1554
Study 34620151 — intervention group
Group type: EXPERIMENTAL
Intervention: Kami-guibi-tang (KGT)
Number of subjects: 30
Study 34620151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35566643 — intervention group
Group type: COMPARATOR
Intervention: Connettivina® Bio Plus (Group A)
Number of subjects: 60
Study 35566643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitostimoline® Plus (Group B)
Number of subjects: 60
Study 35511451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation-volume guaranteed (PCV-VG) with tidal volume set to 6 ml/kg and PEEP at 7 cm H2O
Number of subjects: 0
Study 35511451 — intervention group
Group type: COMPARATOR
Intervention: Volume controlled ventilation (VCV) with tidal volume set to 8 ml/kg
Number of subjects: 0
Study 35487026 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20
Study 35487026 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 33749377 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted childhood BMI
Number of subjects: 14802
Study 33749377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult BMI
Number of subjects: 14802
Study 33749377 — intervention group
Group type: COMPARATOR
Intervention: Adjusted for adult BMI
Number of subjects: 14802
Study 32635933 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMISE protocol (adapted V-MIS protocol)
Number of subjects: 0
Study 32635933 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard V-MIS protocol)
Number of subjects: 0
Study 35224774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained (SR) all-ceramic single crown
Number of subjects: 44
Study 35224774 — intervention group
Group type: COMPARATOR
Intervention: Cemented (CR) all-ceramic single crown
Number of subjects: 44
Study 33231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to pathogen disgust
Number of subjects: 0
Study 33231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Purity concerns
Number of subjects: 0
Study 33231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm-related moral concerns
Number of subjects: 0
Study 33231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen disgust
Number of subjects: 0
Study 33231037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual and injury disgust
Number of subjects: 0
Study 35361440 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Number of subjects: 0
Study 35361440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34117342 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus home‐based foot‐ankle exercises
Number of subjects: 20
Study 34117342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 35674122 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH +)
Number of subjects: 459
Study 35674122 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 459
Study 35138550 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centred Sleep Study Report (PCSR)
Number of subjects: 0
Study 35138550 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 34099065 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA-directed fluid resuscitation
Number of subjects: 140
Study 34099065 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid resuscitation (TRD)
Number of subjects: 140
Study 32289160 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab maintenance therapy (cycles ≥6)
Number of subjects: 267
Study 32289160 — intervention group
Group type: COMPARATOR
Intervention: Blinatumomab induction therapy
Number of subjects: 267
Study 36250938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin-C (IMMC) 40 mg/20 mL, administered 1 day and 4 hours before TURBT
Number of subjects: 99
Study 36250938 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 99
Study 36250938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin-C (IMMC)
Number of subjects: 99
Study 36250938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 34261530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment
Number of subjects: 132
Study 34261530 — intervention group
Group type: COMPARATOR
Intervention: Sham intradermal acupuncture (sham IA) treatment
Number of subjects: 132
Study 35773113 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 474
Study 35773113 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 474
Study 35773113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative use (pretreatment)
Number of subjects: 474
Study 35773113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use (initial 4 weeks of treatment)
Number of subjects: 474
Study 35773113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative use (initial 4 weeks of treatment)
Number of subjects: 474
Study 34518469 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 113
Study 34518469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 34144282 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g EP/calf per day (ECL)
Number of subjects: 27
Study 34144282 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g EP/calf per day (ECH)
Number of subjects: 27
Study 34144282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33824584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885
Study 33824584 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study 33137352 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 42
Study 33137352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise
Number of subjects: 42
Study 33137352 — intervention group
Group type: COMPARATOR
Intervention: No exercise (rest)
Number of subjects: 42
Study 36056408 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat revealed PlGF-based testing
Number of subjects: 0
Study 36056408 — intervention group
Group type: COMPARATOR
Intervention: Repeat concealed testing
Number of subjects: 0
Study 34593565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib monotherapy (600 mg orally twice a day)
Number of subjects: 1000
Study 34593565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib plus nivolumab (600 mg orally twice a day + 480 mg intravenously every 4 weeks)
Number of subjects: 1000
Study 34593565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo + intravenous placebo)
Number of subjects: 1000
Study 35522898 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based model using texture features of myeloblast chromatin patterns to generate a risk score.
Number of subjects: 92
Study 32111181 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with docetaxel 75 mg/m2, cisplatin 75 mg/m2 followed by chemo‐radiotherapy (CRT)
Number of subjects: 300
Study 32111181 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with docetaxel 75 mg/m2, cisplatin 75 mg/m2 followed by chemo‐radiotherapy (CRT) with addition of cetuximab
Number of subjects: 300
Study 32111181 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 300
Study 32111181 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous cell cancer
Number of subjects: 300
Study 34678118 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-CL stem
Number of subjects: 72
Study 34678118 — intervention group
Group type: COMPARATOR
Intervention: Corail stem
Number of subjects: 72
Study 33657192 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria
Number of subjects: 839
Study 33657192 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria with albumin-related threshold
Number of subjects: 839
Study 32868147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in with family members
Number of subjects: 0
Study 36137619 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based CCU and CRC screening intervention offered during breast cancer screening, including vaginal self-sampling kits for HPV testing and faecal immunochemical tests.
Number of subjects: 0
Study 36137619 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based CCU and CRC screening intervention offered during breast cancer screening.
Number of subjects: 0
Study 36137619 — intervention group
Group type: COMPARATOR
Intervention: Standard care provided to women attending control units.
Number of subjects: 0
Study 34294036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal comprehensive care methodology training programme for family caregivers (6 hours total, three sessions of 2 hours each over 3 months, followed by weekly information delivery via postcard)
Number of subjects: 148
Study 34294036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal comprehensive care methodology training programme for family caregivers
Number of subjects: 148
Study 32251216 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol (N = 44)
Number of subjects: 85
Study 32251216 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CON) protocol (N = 41)
Number of subjects: 85
Study 35182789 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered weight loss intervention (22 counseling calls over 12 months)
Number of subjects: 159
Study 35182789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard medical care and brief feedback)
Number of subjects: 159
Study 33528020 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Incremental Step Test (MIST)
Number of subjects: 46
Study 36111187 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-frequency group
Number of subjects: 160
Study 36111187 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-frequency group
Number of subjects: 160
Study 36111187 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-frequency group
Number of subjects: 160
Study 36111187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 33826454 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Poisson regression with robust sandwich variance
Number of subjects: 10
Study 33826454 — intervention group
Group type: COMPARATOR
Intervention: Log-binomial regression
Number of subjects: 10
Study 33826454 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchangeable working correlation
Number of subjects: 10
Study 33826454 — intervention group
Group type: COMPARATOR
Intervention: Independence working correlation
Number of subjects: 10
Study 32234715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 849
Study 32234715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 849
Study 32234715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 35559992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin (standard of care)
Number of subjects: 24
Study 35559992 — intervention group
Group type: COMPARATOR
Intervention: No azithromycin
Number of subjects: 24
Study 33961145 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 33961145 — intervention group
Group type: COMPARATOR
Intervention: Renin-angiotensin blockers
Number of subjects: 0
Study 33961145 — intervention group
Group type: COMPARATOR
Intervention: Steroid-free and mTOR-based immunosuppressive drug combinations
Number of subjects: 0
Study 33961145 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 0
Study 32100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (RANAS model-based intervention delivered over 9 months)
Number of subjects: 320
Study 34865858 — intervention group
Group type: EXPERIMENTAL
Intervention: Toy distraction method (music and movement)
Number of subjects: 60
Study 34865858 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 32382931 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine-derived acellular dermal matrix (MD)
Number of subjects: 18
Study 32382931 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 18
Study 35508035 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal suture (group I)
Number of subjects: 40
Study 35508035 — intervention group
Group type: EXPERIMENTAL
Intervention: External suture (group II)
Number of subjects: 40
Study 33913134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 60
Study 33913134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60
Study 33913134 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 60
Study 35876363 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive interventions for hospice family caregivers
Number of subjects: 525
Study 35876363 — intervention group
Group type: COMPARATOR
Intervention: Demographic and contextual controls
Number of subjects: 525
Study 34399583 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome‐wide association studies
Number of subjects: 0
Study 34399583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study 34399583 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores
Number of subjects: 0
Study 34399583 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics
Number of subjects: 0
Study 34399583 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics of stroke outcome
Number of subjects: 0
Study 35025677 — intervention group
Group type: EXPERIMENTAL
Intervention: White students interacting with White standardized patients (SPs)
Number of subjects: 50
Study 35025677 — intervention group
Group type: COMPARATOR
Intervention: White students interacting with Black standardized patients (SPs)
Number of subjects: 50
Study 35320013 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-10 treatment
Number of subjects: 71
Study 32450083 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Prisoner's Dilemma (RPD) game with independent payoffs for cooperation and defection
Number of subjects: 0
Study 32450083 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized matrix games with non-independent payoffs (RPD game with additive payoffs)
Number of subjects: 0
Study 32450083 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated RPD game with Tit-for-Tat and Always-Defect strategies
Number of subjects: 0
Study 35255832 — intervention group
Group type: EXPERIMENTAL
Intervention: COLM-SST (caraway oil and L-menthol)
Number of subjects: 600
Study 32121000 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb threshold <12.35 g/dL
Number of subjects: 492
Study 32121000 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO altitude-adjusted threshold <12.5 g/dL
Number of subjects: 492
Study 32121000 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted Hb cut-off <12 g/dL
Number of subjects: 492
Study 33497295 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural bupivacaine infiltration (2 mL of 0.5% bupivacaine)
Number of subjects: 100
Study 33497295 — intervention group
Group type: COMPARATOR
Intervention: Control group (spinal anaesthesia only)
Number of subjects: 100
Study 33497295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 34633992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg·kg‐1 ketamine for 40 minutes
Number of subjects: 84
Study 34633992 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 84
Study 34020179 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated nasal surgery (septoplasty and inferior turbinate reduction)
Number of subjects: 35
Study 34020179 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated nasal surgery
Number of subjects: 35
Study 32024228 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids showing total amount of sugar in drinks
Number of subjects: 261
Study 32024228 — intervention group
Group type: COMPARATOR
Intervention: No sugar display (control condition)
Number of subjects: 261
Study 33677450 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan 20 mg daily for 3 months
Number of subjects: 111
Study 33677450 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 8 mg daily for 3 months
Number of subjects: 111
Study 33108379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (protein-energy beverage)
Number of subjects: 1221
Study 33108379 — intervention group
Group type: COMPARATOR
Intervention: Fresco (low-calorie protein-free beverage)
Number of subjects: 1221
Study 35068500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine 10 mg tablet twice daily
Number of subjects: 59
Study 35068500 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine 5 mg tablet once daily
Number of subjects: 59
Study 33172504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 7637
Study 33172504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7637
Study 36203797 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (two capsules containing multi-strain probiotics daily)
Number of subjects: 70
Study 36203797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules daily)
Number of subjects: 70
Study 36095188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 135
Study 36095188 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 135
Study 33772877 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and Cognitive Training (PTCT)
Number of subjects: 314
Study 33772877 — intervention group
Group type: COMPARATOR
Intervention: Physical Training (PT)
Number of subjects: 314
Study 32441759 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game
Number of subjects: 60
Study 35381194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (<100 mmol or <1500 mg/day)
Number of subjects: 806
Study 35381194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 806
Study 35381194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 806
Study 34261992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-active group
Number of subjects: 2195
Study 34261992 — intervention group
Group type: EXPERIMENTAL
Intervention: Total steps per day tracking
Number of subjects: 2195
Study 34261992 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic steps per day tracking
Number of subjects: 2195
Study 34261992 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage agreements
Number of subjects: 2195
Study 34261992 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa statistics
Number of subjects: 2195